3.74
-5.32%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Peijia Medical
Its shares trade on HKEX under the ticker 9996.HK. It has been listed since 15 May 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥830.1m and a net loss of CN¥236.7m. At that date it held total assets of CN¥3.10bn and shareholders' equity of CN¥2.15bn.
Peijia Medical Ltd. engages in the manufacture and sale of medical devices. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2020-05-15. Through its subsidiaries, the Company operates two segments. Transcatheter Valve Therapeutic Business segment is mainly engaged in the development of transcatheter valve therapeutic medical devices. Neurointerventional Business segment is engaged in the research and development of neurointerventional procedural medical devices. The firm's main products under development include TaurusOne, TaurusElite, TaurusNXT and others. The firm operates its businesses primarily in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 15 May 2020
- Employees
- 1,006
- Website
- peijiamedical.com ↗
Leadership
Pay as last reported
- Dr. Yi ZhangExecutive Chairman, Chief Executive Officer, Executive Director, since 2012CN¥2.1m
- Mr. Leo TsaiChief Financial Officer
- Mr. Kongrong PanChief Operating Officer
- Dr. Jian Fong TanChief Technology Officer
- Ms. Dan GaoVice President - Finance, Capital Markets
- Mr. Xin ZhangVice President - Business Development
- Ms. Chen WangGeneral Manager of Achieva
- Ms. Hong YeExecutive Director, Board Secretary, since 2012CN¥3.0m
- Mrs. Ping Ye ZhangExecutive Director, since 2018CN¥177,000
- Ms. Xiaoxiao ZhuangDirector of Sales
- Ms. Hongpeng WangDirector of Marketing
- Mr. Hu PingAssistant to Chief Executive Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Peijia Medical Ltd employs 1006 full-time employees in Suzhou, China.
- Transcatheter Valve Therapeutic Business segment develops TaurusOne medical devices.
- Neurointerventional Business segment focuses on TaurusNXT neurointerventional devices.
Weaknesses
- Peijia Medical Ltd operates primarily in the domestic market of China.
- The company's main products are still under development in China.
- Transcatheter Valve Therapeutic Business segment is limited to domestic market.
Opportunities
- Peijia Medical Ltd's TaurusElite product targets the growing medical device market in China.
- Neurointerventional Business segment can expand into international markets.
- The firm's two business segments can leverage domestic market growth in China.
Threats
- Peijia Medical Ltd faces competition from domestic medical device manufacturers in China.
- The company's reliance on domestic market exposes it to regulatory changes in China.
- Transcatheter Valve Therapeutic Business segment may face supply chain disruptions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.